Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Chubb
Johnson and Johnson
Julphar
Colorcon
McKesson
McKinsey
Federal Trade Commission

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020685

« Back to Dashboard

NDA 020685 describes CRIXIVAN, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug. Additional details are available on the CRIXIVAN profile page.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the indinavir sulfate profile page.
Summary for 020685
Tradename:CRIXIVAN
Applicant:Merck Sharp Dohme
Ingredient:indinavir sulfate
Patents:2
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 020685
Generic Entry Date for 020685*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 020685
Medical Subject Heading (MeSH) Categories for 020685
Suppliers and Packaging for NDA: 020685
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685 NDA Merck Sharp & Dohme Corp. 0006-0571 0006-0571-43 360 CAPSULE in 1 BOTTLE (0006-0571-43)
CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685 NDA Merck Sharp & Dohme Corp. 0006-0573 0006-0573-62 180 CAPSULE in 1 BOTTLE (0006-0573-62)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 400MG BASE
Approval Date:Mar 13, 1996TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 4, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Feb 10, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 200MG BASE
Approval Date:Mar 13, 1996TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 4, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 020685

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
UBS
Baxter
McKesson
Chinese Patent Office
Federal Trade Commission
US Army
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.